Nadroparin (N = 765*) | Placebo (N = 378*) | |
---|---|---|
Khorana Risk score | ||
0 | 38.2 (292/765) | 36.8 (139/378) |
1 | 32.2 (246/765) | 30.4 (115/378) |
2 | 21 (161/765) | 21.7 (82/378) |
3 | 8 (61/765) | 9.8 (37/378) |
4 | 0.5 (4/765) | 1.1 (4/378) |
5 | 0.1 (1/765) | 0.3 (1/378) |
Khorana Risk group* | ||
High risk | 8.6 (66/765) | 11.1 (42/378) |
Intermediate risk | 53.2 (407/765) | 52.1 (197/378) |
Low risk | 38.2 (292/765) | 36.8 (139/378) |